<SEC-DOCUMENT>0001213900-21-041587.txt : 20210922
<SEC-HEADER>0001213900-21-041587.hdr.sgml : 20210922
<ACCEPTANCE-DATETIME>20210811135104
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-21-041587
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20210811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		830 MENLO AVENUE, SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		830 MENLO AVENUE, SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>180 LIFE SCIENCES CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>3000 El Camino Real, Bldg. 4, Suite 200</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Palo Alto, CA 94306</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>BY EDGAR</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">August 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">U.S. Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attn:&#9;&nbsp;&nbsp;Jessica Ansart &amp; Laura Crotty</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>180 Life Sciences Corp.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Post-Effective Amendment No. 1 to Form S-1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed August 2, 2021</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File No. 333-249539</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dear Sir / Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On behalf of our client, 180 Life Sciences Corp. (the
&ldquo;<U>Company</U>&rdquo;), we hereby submit this letter in response to the comments set forth in that certain letter dated August
9, 2021 from the staff (the &ldquo;<U>Staff</U>&rdquo;) of the U.S. Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
to the Company, relating to Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 that the Company filed with the Commission
on August 2, 2021 (File No. 333-249539) (the &ldquo;<U>Registration Statement</U>&rdquo;).&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is responding to the Staff&rsquo;s comments
by proposing to file a Post-Effective Amendment No. 2 to the Registration Statement, as set forth below. For your convenience, the Staff&rsquo;s
comments have been retyped herein in bold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Comment 1</U>&#9;<U>General</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>We note that the Form S-1 declared effective on
November 2, 2020 (the &ldquo;<U>Original Registration Statement</U>&rdquo;) registered the resale of 9,108,836 shares of common stock
and that you seek to now register the resale of an additional 175,000 common shares via post-effective amendment. Please explain why you
believe you are able to do so in light of the general prohibition against adding securities by means of a post-effective amendment contained
in Securities Act Rule 413(a). Refer also to Securities Act Rule Compliance and Disclosure Interpretation 210.01.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Response</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When the Company filed the Original Registration Statement,
such registration statement registered, among other things, the resale of an aggregate of 2,592,195 shares of the common stock, par value
$0.0001 per share, of the Company (&ldquo;<U>Common Stock</U>&rdquo;), issuable upon the conversion of certain secured convertible 10%
original issue discount promissory notes in the aggregate principal amount of $4,713,077.39 (after giving effect to the 10% original issue
discount), plus interest thereon at the rate of 10% per annum for one year, that were issued to investors pursuant to (A) a Securities
Purchase Agreement dated June 12, 2020 by and between the Company and the investors signatory thereto (the &ldquo;<U>June SPA</U>&rdquo;)
and (B) a Securities Purchase Agreement dated September 8, 2020 by and between the Company and Alpha Capital Anstalt (the &ldquo;<U>September
SPA</U>&rdquo;; and such investor under the September SPA, &ldquo;<U>Alpha</U>&rdquo;). The number of shares registered for resale with
respect to the notes issued pursuant to the June SPA and the September SPA was based on a floor conversion price (after giving effect
to potential anti-dilution adjustments) of $2.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More specifically, of the shares of Common Stock that
were registered for resale on the Original Registration Statement upon the conversion of the secured convertible promissory notes, 611,112
shares were registered for resale by Alpha upon the conversion of $1,111,111 principal amount of secured convertible promissory notes
that were issued to Alpha pursuant to the September SPA (the &ldquo;<U>Alpha Notes</U>&rdquo;), plus accrued and unpaid interest thereon,
based upon a conversion price of $2.00 per share. Of such 611,112 shares of Common Stock that were registered for resale by Alpha upon
conversion of the Alpha Notes, a total of 333,352 shares of Common Stock had been issued to it prior to the date of the Mutual Release
&amp; Settlement Agreement dated July 31, 2021 by and between the Company and Alpha (the &ldquo;<U>Settlement Agreement</U>&rdquo;), of
which a total of 94,960 shares of Common Stock were still held by it at such time, and a total of $316,111.11 principal balance of the
Alpha Notes remained outstanding immediately prior to the Settlement Agreement (the &ldquo;<U>Remaining Note Balance</U>&rdquo;). A total
of 277,760 shares of Common Stock that had been registered on the Original Registration Statement for resale by Alpha upon conversion
of the Alpha Notes had not been issued to Alpha and thus remained available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the determination by the Board of Directors of the Company
on January 28, 2021 that the consolidated financial statements of the Company, which were prepared by the former management of the Company,
for the interim period ended June 30, 2020, which were included in the Original Registration Statement, should no longer be relied upon
due to errors in the consolidated financial statements and the related disclosures and should be restated, the Original Registration Statement
(and the prospectus contained therein) became unavailable for the resale of the shares of Common Stock thereunder. The unavailability
of the Original Registration Statement (and the prospectus contained therein) constituted a default under the June SPA and the September
SPA, as well as under the secured convertible promissory notes that were issued thereunder and the Registration Rights Agreements that
were entered into in connection therewith. On February 5, 2021, the Company filed an Amendment No. 1 to its Quarterly Report on Form 10-Q
for the fiscal period ended June 30, 2020 to address these issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to resolve the disputes that had arisen between
the Company and Alpha relating to the defaults under the September SPA and the Alpha Notes, on July 31, 2021, the Company and Alpha entered
into the Settlement Agreement. Pursuant to the Settlement Agreement, in full and complete consideration for all amounts owed
by the Company under the Alpha Notes and related agreements, including the September SPA, including the conversion of the Remaining Note
Balance, all penalties, fees and other costs or expenses, including, but not limited to, events of default, Alpha agreed to exchange the
Alpha Notes for 150,000 shares of Common Stock (&ldquo;<U>Conversion Shares</U>&rdquo;) and a warrant (the &ldquo;<U>Warrant</U>&rdquo;)
to purchase 25,000 shares of Common Stock. The Settlement Agreement specifically states that the Conversion Shares shall be treated as
&ldquo;Conversion Shares&rdquo; under the Alpha Notes, with all the rights and privileges thereof. The Settlement Agreement is more fully
described in a Current Report on Form 8-K that the Company filed with the Commission on August 2, 2021 (the &ldquo;<U>August 8-K</U>&rdquo;).
The Settlement Agreement was filed as Exhibit 10.1 to the August 8-K and the form of Warrant was filed as Exhibit 4.1 to the August 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon the foregoing, it is our belief that the Conversion Shares
that were issued to Alpha pursuant to the Settlement Agreement should be considered as part of the shares of Common Stock that were registered
for resale by Alpha upon conversion of the Alpha Notes (including conversion of the Remaining Note Balance) pursuant to the Original Registration
Statement, and not as newly registered shares. Subject to your concurrence with this position, the Company will file a Post-Effective
Amendment No. 2 to the Registration Statement to remove the 150,000 Conversion Shares as additional shares being registered, and also
to remove the resale of the 25,000 shares of Common Stock issuable upon exercise of the Warrant (which shares underlying the Warrant will
remain unregistered and not part of the Registration Statement). To be clear, no additional securities would be registered on Post-Effective
Amendment No. 2 to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We would appreciate your response to the proposed
approach outlined above at your earliest convenience. If you have any further questions or comments, or would like to discuss this response
letter, please feel free to call me at (212) 326-0468.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael T. Campoli</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael T. Campoli</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pryor Cashman LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">cc:&#9;&nbsp;Ozan Pamir</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
